Treatment of Mild Bacterial Conjunctivitis in Immune-Competent Adults
This protocol covers the management of mild bacterial conjunctivitis in immune-competent adults — a presentation that is commonly self-limited yet may benefit from treatment to achieve earlier resolution.
Mild bacterial conjunctivitis in immune-competent adults is typically self-limited and can resolve spontaneously without specific treatment. When treatment is indicated, the goal is to achieve clinical and microbiological remission within the first days of therapy.
Treatment Goal
Clinical and microbiological remission of bacterial conjunctivitis within the first days of treatment.
Treatment Approach (partial summary)
Management centres on topical antibiotic therapy, selected empirically, with an alternative topical agent available in settings where antibiotic access is limited.
Full regimen details, agent selection rationale, and complete criteria are in the structured protocol →
References
- Mild bacterial conjunctivitis is usually self-limited, and it typically resolves spontaneously without specific treatment in immune-competent adults.
- The choice of antibiotic is usually empiric.
- Because a 5- to 7-day course of a broad-spectrum topical antibiotic is usually effective, the most convenient or least expensive option can be selected; there is no clinical evidence suggesting the superiority of any particular antibiotic.
- Povidone-iodine 1.25% ophthalmic solution may be as effective as topical antibiotic therapy for treating bacterial conjunctivitis and could be considered when access to antibiotics is limited, such as in the low- to middle-income countries.
- Use of topical antibacterial therapy is associated with earlier clinical and microbiological remission compared with placebo in days 2 to 5 of treatment.
View source ↗